Log in or Sign up for Free to view tailored content for your specialty!
Rheumatoid Arthritis News
Newly diagnosed psoriatic disease associated with autoimmune disease risk
Newly diagnosed psoriatic disease may bring with it a significantly increased risk for autoimmune disease incidences, according to a study.
Precision medicine in rheumatoid arthritis: Hype or hope?
I heard my first lecture about personalized or precision medicine in the early 1980s.
Log in or Sign up for Free to view tailored content for your specialty!
Taking ‘shots on goal’: The continuing fight to bring precision medicine to rheumatology
Patients across health care specialties have in recent years come to expect some form of individually tailored care — or precision medicine — as part of their disease management.
FDA grants 510(k) clearance to Werfen’s reagent for connective tissue disease testing
The FDA has granted 510(k) clearance to Werfen for its Aptiva Connective Tissue Disease Essential reagent to assist in the diagnosis of patients with autoimmune diseases, according to a manufacturer press release.
‘Pain is the most important symptom’: Helping patients navigate the dangers of OTC NSAIDs
For patients with diseases such as lupus or rheumatoid arthritis who take low-dose drugs at lower frequencies, the relief afforded by over-the-counter drugs such as ibuprofen and naproxen can be a boon.
Opioids carry increased risk for death vs NSAIDs in patients with rheumatoid arthritis
In patients with rheumatoid arthritis, NSAIDs and opioids demonstrate similar risks for major adverse cardiovascular events, while opioids exhibit higher rates of all-cause mortality and venous thromboembolism, according to data.
Rheumatoid arthritis patients with higher paraoxonase levels have lower MACE, cancer rates
Patients receiving tofacitinib for rheumatoid arthritis with higher paraoxonase activity over time demonstrate a lower risk for major adverse cardiovascular events and malignancy, according to data published in the Journal of Rheumatology.
FDA approves Abrilada as second interchangeable adalimumab biosimilar
The FDA has approved Abrilada as the second interchangeable biosimilar to adalimumab, according to a press release from Pfizer.
Boehringer Ingelheim Humira biosimilar available at low wholesale acquisition cost
Adalimumab-adbm injection is now available at a low wholesale acquisition cost, Boehringer Ingelheim announced in a company press release.
Abatacept, certolizumab pegol superior to conventional therapy for rheumatoid arthritis
Patients with rheumatoid arthritis who receive abatacept or certolizumab pegol achieve clinical remission at higher rates than those receiving active conventional therapy, according to data published in Annals of the Rheumatic Diseases.
-
Headline News
FDA warns of potential liver injury with Veozah for menopausal hot flashes
September 12, 20242 min read -
Headline News
Video games improved mental health during COVID-19 pandemic
September 12, 20242 min read -
Headline NewsSeptember 12, 20240 min read
-
Headline News
FDA warns of potential liver injury with Veozah for menopausal hot flashes
September 12, 20242 min read -
Headline News
Video games improved mental health during COVID-19 pandemic
September 12, 20242 min read -
Headline NewsSeptember 12, 20240 min read